Therefore, it is hypothesized that RPRD1A may exert its downregulatory effect on molecules such as SOX9 via the Wnt/β-catenin signaling pathway, thereby inhibiting the stem cell-like properties of GC and enhancing sensitivity to chemotherapeutic agents. The gene discussed is SOX9; the disease is gastric cancer.